论文部分内容阅读
目的:观察真武汤联合紫杉醇腹腔热灌注化疗治疗中晚期上皮性卵巢癌合并腹腔积液的临床疗效。方法:将60例上皮性卵巢癌合并腹腔积液患者随机分为治疗组和对照组各30例,均治疗3个疗程后,对比两组患者治疗后肿瘤的控制情况、腹腔积液的改善情况、生活质量及不良反应。结果:治疗后肿瘤控制有效率治疗组(76.7%)与对照组(70.0%)比较,差异无统计学意义(P>0.05);治疗组患者治疗后生活质量明显改善,与对照组比较,差异有统计学意义(P<0.05);治疗后治疗组腹腔积液控制率为86.7%,对照组的腹腔积液控制率为53.3%,两组比较,差异有统计学意义(P<0.05)。结论:真武汤联合紫杉醇腹腔热灌注化疗治疗上皮性卵巢癌合并腹腔积液有较好疗效,可控制卵巢肿瘤、腹腔积液,改善患者生活质量,其安全性好。
Objective: To observe the clinical efficacy of Zhenwu Decoction combined with paclitaxel intraperitoneal hyperthermic perfusion chemotherapy in the treatment of advanced epithelial ovarian cancer with ascites. Methods: Sixty patients with epithelial ovarian cancer complicated with ascites were randomly divided into treatment group (30 cases) and control group (30 cases). After three courses of treatment, the control of tumor and the improvement of ascites were compared between the two groups , Quality of life and adverse reactions. Results: After treatment, the effective rate of tumor control in treatment group (76.7%) was significantly higher than that in control group (70.0%) (P> 0.05); the quality of life in treatment group was significantly improved after treatment (P <0.05). After treatment, the control rate of ascites was 86.7% in the treatment group and 53.3% in the control group. The difference between the two groups was statistically significant (P <0.05). Conclusion: Zhenwu decoction combined with paclitaxel intraperitoneal hyperthermic perfusion chemotherapy has good curative effect on epithelial ovarian cancer with ascites, which can control ovarian tumors and ascites and improve the quality of life of patients with good safety.